NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENE shares have decreased by 13.5% and is now trading at $11.00. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenon Pharmaceuticals.

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Xenon Pharmaceuticals.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) issued its quarterly earnings data on Monday, March, 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by $0.54. The biopharmaceutical company earned $3.33 million during the quarter, compared to analyst estimates of $25 million. View Xenon Pharmaceuticals' earnings history.

4 analysts have issued 1 year target prices for Xenon Pharmaceuticals' shares. Their forecasts range from $18.00 to $25.00. On average, they expect Xenon Pharmaceuticals' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View analysts' price targets for Xenon Pharmaceuticals.

News articles about XENE stock have been trending extremely negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutXenon Pharmaceuticals.

Xenon Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 591,300 shares, an increase of 29.8% from the February 27th total of 455,400 shares. Based on an average daily volume of 261,900 shares, the days-to-cover ratio is presently 2.3 days. Currently, 2.6% of the shares of the stock are sold short. View Xenon Pharmaceuticals' Current Options Chain.

Some companies that are related to Xenon Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Theravance Biopharma (TBPH), Akcea Therapeutics (AKCA), Karyopharm Therapeutics (KPTI), Constellation Pharmaceuticals (CNST), Pacira Biosciences (PCRX), Dicerna Pharmaceuticals (DRNA), IGM Biosciences (IGMS), BELLUS Health (BLUSF), Corcept Therapeutics (CORT), Innoviva (INVA), Ligand Pharmaceuticals (LGND) and Tricida (TCDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Heron Therapeutics (HRTX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (7.53%), NEA Management Company LLC (3.83%), Point72 Asset Management L.P. (3.31%), Renaissance Technologies LLC (2.30%), Parkman Healthcare Partners LLC (2.27%) and Granite Point Capital Management L.P. (1.05%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View institutional ownership trends for Xenon Pharmaceuticals.

XENE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Granite Point Capital Management L.P., Russell Investments Group Ltd., Bank of New York Mellon Corp, California Public Employees Retirement System, and Bank of Montreal Can. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab, and Simon N Pimstone. View insider buying and selling activity for Xenon Pharmaceuticals.

XENE stock was purchased by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, NEA Management Company LLC, Ikarian Capital LLC, BVF Inc. IL, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Marshall Wace LLP, and Cubist Systematic Strategies LLC. View insider buying and selling activity for Xenon Pharmaceuticals.

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XENE stock can currently be purchased for approximately $11.00.

Xenon Pharmaceuticals has a market capitalization of $384.56 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe. View additional information about Xenon Pharmaceuticals.

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]